A scarce, regulated Brazilian medical-education king building a physician “super-app” ecosystem—mispriced despite visible seat-maturation growth and fortress cash generation.
Overview
Afya is Brazil’s dominant medical education group and an emerging digital health ecosystem, differentiated from generalist education providers by a defensive, scarcity-driven niche with high regulatory barriers and inelastic demand. The core thesis is the power of undergraduate seat scale and maturation: with ~3,753 approved medical seats (Q3’25), Afya has a built-in multi-year growth runway as cohorts stack over a six-year cycle, largely insulated from near-term macro volatility and supporting margin expansion due to low incremental costs versus high tuition (>R$9,000/month) that typically rises above inflation. The company is also building a physician “super-app” approach—continuing education plus practice tools—aiming to monetize doctors through residency preparation and decades of clinical practice, with platforms reaching roughly one-third of Brazilian physicians. Financial execution in 2024–2025 has been strong: 9M25 net revenue ~R$2.78B (+13.4% YoY), Adjusted EBITDA ~R$1.29B (+18.5%) with margin ~46.4% (+200 bps), robust cash conversion (~101.5%), and deleveraging to ~0.8x net debt/EBITDA. Key risks are regulatory unpredictability (MEC authorization freezes/changes), high Brazilian rates and FX/inflation, and digital execution amid competition and churn. Overall, Afya appears like a high-quality compounder trading at discounted multiples versus fundamentals.